Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma.

@article{Schmidinger2012TherapyMO,
  title={Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma.},
  author={Manuela P. Schmidinger and Jutta Bergler-Klein},
  journal={International journal of urology : official journal of the Japanese Urological Association},
  year={2012},
  volume={19 9},
  pages={796-804}
}
Targeted agents have significantly improved outcomes in patients with metastatic renal cell carcinoma, and are changing long-term expectations in these patients. Experience with these agents highlights a distinct safety and tolerability profile, differing from that observed with conventional chemotherapy and radiotherapy. Cardiovascular adverse events have been observed when treating with targeted agents. This is of particular importance for patients with metastatic renal cell carcinoma who are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

The use of sunitinib in renal cell carcinoma: where are we now?

Expert review of anticancer therapy • 2014
View 5 Excerpts
Highly Influenced

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…